- Home
- NAUT vs LIEN Comparison
NAUT vs LIEN Comparison
Compare NAUT & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- LIEN
- Stock Information
- Founded
- NAUT 2016
- LIEN 2021
- Country
- NAUT United States
- LIEN United States
- Employees
- NAUT N/A
- LIEN N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- LIEN
- Sector
- NAUT Industrials
- LIEN
- Exchange
- NAUT Nasdaq
- LIEN NYSE
- Market Cap
- NAUT 91.5M
- LIEN 234.6M
- IPO Year
- NAUT N/A
- LIEN 2022
- Fundamental
- Price
- NAUT $0.69
- LIEN $10.29
- Analyst Decision
- NAUT Hold
- LIEN Buy
- Analyst Count
- NAUT 2
- LIEN 2
- Target Price
- NAUT $3.88
- LIEN N/A
- AVG Volume (30 Days)
- NAUT 553.0K
- LIEN 56.1K
- Earning Date
- NAUT 07-29-2025
- LIEN 08-07-2025
- Dividend Yield
- NAUT N/A
- LIEN 13.25%
- EPS Growth
- NAUT N/A
- LIEN 30.25
- EPS
- NAUT N/A
- LIEN 1.15
- Revenue
- NAUT N/A
- LIEN $30,828,508.00
- Revenue This Year
- NAUT N/A
- LIEN $154.46
- Revenue Next Year
- NAUT N/A
- LIEN $10.64
- P/E Ratio
- NAUT N/A
- LIEN $8.90
- Revenue Growth
- NAUT N/A
- LIEN 151.96
- 52 Week Low
- NAUT $0.66
- LIEN $9.70
- 52 Week High
- NAUT $3.09
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- NAUT 43.84
- LIEN N/A
- Support Level
- NAUT $0.69
- LIEN N/A
- Resistance Level
- NAUT $0.85
- LIEN N/A
- Average True Range (ATR)
- NAUT 0.06
- LIEN 0.00
- MACD
- NAUT 0.00
- LIEN 0.00
- Stochastic Oscillator
- NAUT 8.70
- LIEN 0.00
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.